Fig. 2.
(a) Forest plot showing efficacy outcomes on cardiovascular efficacy. (b) Common safety outcomes of SGLT2-I in patients with high risk of cardiovascular disease. SGLT2-I, sodium-glucose cotransporter 2 inhibitors.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.